Stockholm, Sweden, April 29, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2019 on Thursday, May 9, 2019 at 08:00 a.m. CET.
BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on May 9, at 09:30 – 10:30 a.m. CET.
Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the first quarter of 2019 followed by a Q&A-session.
- Sweden: + 46 8 505 583 53
- Denmark: + 45 781 501 07
- Germany: + 49 692 222 203 80
- The Netherlands: + 31 207 219 495
- Norway: + 47 235 002 36
- Switzerland: + 41 225 805 976
- UK: + 44 333 300 9262
- US: + 1 833 526 8381
The webcast will afterwards also be available on demand at BioArctic’s corporate website www.bioarctic.com, Investors, Financial presentations.
For more information, please contact:
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.
BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). www.bioarctic.com
This information was submitted for publication at 08:00 a.m. CET on April 29, 2019.